New insights into autoimmune liver diseases

Kumagi, Teru; Alswat, Khalid; Hirschfield, Gideon M.; Heathcote, Jenny

doi:10.1111/j.1872-034x.2008.00366.x

Cited by 15 publications

(19 citation statements)

References 213 publications

(342 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Diseases of the bile ducts (primary biliary cirrhosis and primary sclerosing cholangitis) that evolve to liver cirrhosis are extremely rare in children. Both are followed by the significant increase of liver enzymes, alkaline phosphatase and yGT, whichthat are significantly higher compared with those found in CHF patients and do not have the same visualisation techniques for extra testing [10]. Cystic changes in the liver and in primary biliary cirrhosis antimitochondrial antibodies were not found in any of these diseases.…”

Section: Discussionmentioning

confidence: 83%

Congenital hepatic fibrosis

Raskovic¹,

Vuletic²,

Igrutinović³

et al. 2013

Ser J Exp Clin Res

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 83%

Congenital hepatic fibrosis

Raskovic¹,

Vuletic²,

Igrutinović³

et al. 2013

Ser J Exp Clin Res

View full text Add to dashboard Cite

show abstract

“…Patients with other liver conditions who attend the liver clinic (e.g., nonalcoholic fatty liver disease, hepatitis B and autoimmune liver disease) have markedly different characteristics to patients with CHC, hence they are unsuitable comparators [31–33]. Within the local community, the recruitment of a “healthy” control group of suitable sample size matched for BMI, age, gender, ethnicity, education, and metabolic comorbidity was also considered unfeasible.…”

Section: Discussionmentioning

confidence: 99%

Poor Perception of Body Weight Category amongst the Overweight and Obese with Chronic Hepatitis C: A Target for Intervention

et al. 2011

View full text Add to dashboard Cite

Obesity in chronic hepatitis C (CHC) is associated with adverse hepatic and metabolic outcomes. This prospective study evaluates the agreement between self-perceived body weight (BW) status and measured body mass index (BMI) category and factors associated with its underestimation in CHC. Body size perception was measured with the Contour Drawing Rating Scale. Two hundred and seventy-three patients with CHC (overweight 45%, obese 18%) participated in this study. Although both overweight and obese demonstrated good body size perception, agreement between perceived BW and measured BMI categories was poor (κ = 0.315, 95% CI 0.231–0.399); 33% of overweight/obese respondents considered themselves normal or underweight. Male gender (OR 2.84) and overweight (OR 2.42) or obese BMI (OR 14.19) were associated with underestimation of BW category. Targeted interventions are needed to improve body weight perception, thereby enhancing the uptake of health advice on management of excess body weight in CHC.

show abstract

“…Although becoming much clearer, the exact pathogenesis of the disease and difference in the patterns of disease progression remain unclear 136. In this regard, newly developed animal models as well as currently undergoing genome-wide association studies worldwide may provide us with a better understanding of PBC 7,137,138…”

Section: Future Directions and Conclusionmentioning

confidence: 99%

Natural history and management of primary biliary cirrhosis

Al-Harthy¹,

Kumagi²

2012

HMER

Self Cite

View full text Add to dashboard Cite

Primary biliary cirrhosis (PBC) is a chronic inflammatory autoimmune disease that mainly targets the cholangiocytes of the interlobular bile ducts in the liver. It is a rare disease with prevalence of less than one in 2000. Its prevalence in developing countries is increasing presumably because of growth in recognition and knowledge of the disease. PBC is thought to result from a combination of multiple genetic factors and superimposed environmental triggers. The contribution of the genetic predisposition is evidenced by familial clustering. Several risk factors, including exposure to infectious agents and chemical xenobiotics, have been suggested. Common symptoms of the disease are fatigue and pruritus, but most patients are asymptomatic at first presentation. The prognosis of PBC has improved because of early diagnosis and use of ursodeoxycholic acid, the only established medical treatment for this disorder. When administered at adequate doses of 13–15 mg/kg/day, up to two out of three patients with PBC may have a normal life expectancy without additional therapeutic measures. However, some patients do not respond adequately to ursodeoxycholic acid and might need alternative therapeutic approaches.

show abstract

New insights into autoimmune liver diseases

Cited by 15 publications

References 213 publications

Congenital hepatic fibrosis

Congenital hepatic fibrosis

Poor Perception of Body Weight Category amongst the Overweight and Obese with Chronic Hepatitis C: A Target for Intervention

Natural history and management of primary biliary cirrhosis

Contact Info

Product

Resources

About